Hoth Therapeutics Inc. (HOTH)
$0.82
$-0.07
(-7.93%)
As on 17-Jul-2026 09:30EDT
Market cap
$26 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
4.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.9 %
-
ROCE
-- %
-
Industry P/E
37.31
-
EV/EBITDA
0.4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.8
-
Face value
--
-
Shares outstanding
19,127,643
7 Years Aggregate
CFO
$-43.72 Mln
EBITDA
$-50.20 Mln
Net Profit
$-53.24 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Hoth Therapeutics (HOTH)
| -17.2 | -26.5 | 10.2 | -38.9 | -33.4 | -52.7 | -- |
|
BSE Sensex*
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Hoth Therapeutics (HOTH)
| 32.3 | -47.8 | -81.5 | -52.7 | -72.2 | -61.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Hoth Therapeutics (HOTH)
|
0.8 | 26.0 | 0.0 | -13.3 | -- | -185.6 | -- | 4.5 |
| 17.5 | 6,109.1 | 3,117.6 | 157.4 | 14.7 | -- | 37.3 | 190.1 | |
| 199.0 | 10,424.8 | 776.6 | -191.6 | -17.6 | -223.4 | -- | 129.6 | |
| 76.6 | 14,974.8 | 691.8 | -696.2 | -89.1 | -- | -- | 123.7 | |
| 113.9 | 12,310.3 | 830.8 | 54.9 | 3.2 | 8.1 | 264.8 | 17.9 | |
| 24.1 | 11,971.8 | 5,020.0 | -199.0 | 1.6 | -3 | -- | 1.8 | |
| 7.7 | 5,233.7 | 7,430.4 | 452.5 | 17.6 | 7 | 10 | 0.8 | |
| 280.5 | 5,591.7 | 290.5 | 197.2 | 82.5 | 19.9 | 28.9 | 5.9 | |
| 67.7 | 6,058.9 | 450.9 | 138.6 | 39.1 | 115.6 | 50.1 | 32.1 | |
| 141.4 | 8,865.6 | 431.8 | -136.7 | -30.8 | -30.3 | -- | 21.5 |
Shareholding Pattern
View DetailsAbout Hoth Therapeutics (HOTH)
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in the United States. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with... rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; and HT-004 for treatment of asthma and allergies using inhalational administration. The company is developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. The company was incorporated in 2017 and is based in Hoboken, New Jersey. Read more
-
President, CEO & Chairman
Mr. Robb Knie
-
President, CEO & Chairman
Mr. Robb Knie
-
Headquarters
Hoboken, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Hoth Therapeutics (HOTH)
What is the current share price of Hoth Therapeutics Inc (HOTH) Today?
The share price of Hoth Therapeutics Inc (HOTH) is $0.82 (NASDAQ) as of 17-Jul-2026 09:30 EDT. Hoth Therapeutics Inc (HOTH) has given a return of -33.37% in the last 3 years.
What is the current PB & PE ratio of Hoth Therapeutics Inc (HOTH)?
Since, TTM earnings of Hoth Therapeutics Inc (HOTH) is negative, P/E ratio is not available.
The P/B ratio of Hoth Therapeutics Inc (HOTH) is 4.55 times as on 17-Jul-2026, a 41 discount to its peers’ median range of 7.75 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.23 |
2.50 |
2024 |
-0.67 |
0.79 |
2023 |
-0.80 |
0.66 |
2022 |
-0.82 |
1.82 |
2021 |
-0.04 |
0.06 |
What is the 52 Week High and Low of Hoth Therapeutics Inc (HOTH)?
The 52-week high and low of Hoth Therapeutics Inc (HOTH) are Rs 2.20 and Rs 0.49 as of 30-Aug-2026.
What is the market cap of Hoth Therapeutics Inc (HOTH)?
Hoth Therapeutics Inc (HOTH) has a market capitalisation of $ 26 Mln as on 17-Jul-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Hoth Therapeutics Inc (HOTH)?
Before investing in Hoth Therapeutics Inc (HOTH), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.